skip to Main Content

Public Investments in TB Medicine Bedaquiline Far Exceed Those of Developer Johnson & Johnson

Archives:

October 31, 2019 – TAG presented an analysis at the 50th Union World Conference on Lung Health, which found that that total public expenditures on the development of bedaquiline, an important medicine for drug-resistant tuberculosis, far exceed those of Johnson & Johnson, the originator company.

 

Back To Top